These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27331218)

  • 1. Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT).
    Otte A
    Hell J Nucl Med; 2016; 19(2):182. PubMed ID: 27331218
    [No Abstract]   [Full Text] [Related]  

  • 2. GEPNETs update: Radionuclide therapy in neuroendocrine tumors.
    van der Zwan WA; Bodei L; Mueller-Brand J; de Herder WW; Kvols LK; Kwekkeboom DJ
    Eur J Endocrinol; 2015 Jan; 172(1):R1-8. PubMed ID: 25117465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.
    Kwekkeboom DJ; Krenning EP; Lebtahi R; Komminoth P; Kos-Kudła B; de Herder WW; Plöckinger U; ;
    Neuroendocrinology; 2009; 90(2):220-6. PubMed ID: 19713714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Peptide receptor radionuclide therapy of neuroendocrine tumors].
    Arveschoug AK; Hjorthaug K; Rehling M; Højgaard L; Mortensen J; Oturai PS
    Ugeskr Laeger; 2009 Mar; 171(13):1073. PubMed ID: 19321068
    [No Abstract]   [Full Text] [Related]  

  • 5. Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment?
    Virgolini I;
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1949-54. PubMed ID: 26268679
    [No Abstract]   [Full Text] [Related]  

  • 6. Peptide receptor radionuclide therapy of neuroendocrine tumours.
    Brabander T; Teunissen JJ; Van Eijck CH; Franssen GJ; Feelders RA; de Herder WW; Kwekkeboom DJ
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):103-14. PubMed ID: 26971847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward.
    Feijtel D; de Jong M; Nonnekens J
    Curr Top Med Chem; 2020; 20(32):2959-2969. PubMed ID: 32101125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
    Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors.
    Bodei L; Kidd M; Prasad V; Modlin IM
    Front Horm Res; 2015; 44():198-215. PubMed ID: 26303714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.
    Sonbol MB; Halfdanarson TR; Hilal T
    JAMA Oncol; 2020 Jul; 6(7):1086-1092. PubMed ID: 32297906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
    Bodei L; Pepe G; Paganelli G
    Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide receptor radionuclide therapy: an overview.
    Dash A; Chakraborty S; Pillai MR; Knapp FF
    Cancer Biother Radiopharm; 2015 Mar; 30(2):47-71. PubMed ID: 25710506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions.
    Tapia Rico G; Li M; Pavlakis N; Cehic G; Price TJ
    Cancer Treat Rev; 2018 May; 66():1-6. PubMed ID: 29602040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.
    van Vliet EI; Teunissen JJ; Kam BL; de Jong M; Krenning EP; Kwekkeboom DJ
    Neuroendocrinology; 2013; 97(1):74-85. PubMed ID: 22237390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.
    Bodei L; Cremonesi M; Kidd M; Grana CM; Severi S; Modlin IM; Paganelli G
    Thorac Surg Clin; 2014 Aug; 24(3):333-49. PubMed ID: 25065935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.
    Lo Russo G; Pusceddu S; Prinzi N; Imbimbo M; Proto C; Signorelli D; Vitali M; Ganzinelli M; Maccauro M; Buzzoni R; Seregni E; de Braud F; Garassino MC
    Tumour Biol; 2016 Oct; 37(10):12991-13003. PubMed ID: 27460087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours.
    Kaewput C; Vinjamuri S
    Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
    de Visser M; Verwijnen SM; de Jong M
    Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid neoplasms after chemotherapy and PRRT: myth and reality.
    Bodei L; Modlin IM; Luster M; Forrer F; Cremonesi M; Hicks RJ; Ezziddin S; Kidd M; Chiti A
    Endocr Relat Cancer; 2016 Aug; 23(8):C1-7. PubMed ID: 27353035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.